Sponsor Check › Person
Related person on Form D filings · address states as listed: CA, FL, WA, OH, NJ, TX · listed Mar 19, 2009 → Sep 3, 2024
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:56 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:56 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:56 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
1 of 80 offerings reports sales commissions totalling $2,772,796; 1 reports finder's fees totalling $150,000; 11 report proceeds to related persons totalling $3,350,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Sep 3, 2024 D/A File 021-509796 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 8, 2024 D/A File 021-502813 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 13, 2023 D File 021-486781 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 26, 2023 D File 021-482682 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 13, 2022 D File 021-458709 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 16, 2022 D/A File 021-443584 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 27, 2022 D/A File 021-421560 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 19, 2021 D File 021-421870 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 13, 2021 D/A File 021-412895 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 1, 2020 D File 021-376899 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 19, 2020 D/A File 021-365900 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 12, 2020 D/A File 021-346015 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 14, 2020 D File 021-360651 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 30, 2020 D/A File 021-355808 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 6, 2019 D/A File 021-346548 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 2, 2019 D File 021-336244 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 27, 2019 D File 021-333703 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 14, 2019 D File 021-332870 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 16, 2019 D/A File 021-328716 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 21, 2018 D File 021-328802 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 23, 2018 D File 021-324130 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 20, 2018 D File 021-319627 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 17, 2018 D File 021-319552 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 27, 2018 D File 021-317976 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 1, 2018 D File 021-313687 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 15, 2018 D File 021-312449 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 19, 2018 D File 021-310594 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 27, 2017 D/A File 021-299288 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 25, 2017 D File 021-297412 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 10, 2017 D File 021-290279 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 31, 2017 D/A File 021-287104 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 3, 2017 D/A File 021-282032 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 15, 2017 D File 021-282659 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 8, 2017 D File 021-280243 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 16, 2016 D File 021-274614 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 16, 2016 D File 021-274607 | $0 | $0 | $0 The Issuer is obligated to pay a management fee to the General Partner (or an affiliate thereof). | None listed on this filing |
| EDGAR ↗ | Oct 18, 2016 D File 021-272762 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 5, 2016 D File 021-271890 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 24, 2016 D File 021-269459 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 10, 2016 D File 021-268648 | $0 | $0 | $1,000,000 Repayment of promissory note to a director of the Issuer. | None listed on this filing |
| EDGAR ↗ | Mar 15, 2016 D File 021-259339 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 20, 2015 D File 021-251658 | $2,772,796 (est.) | $0 | $0 | Piper Jaffray & Co. BrokerCheck CRD 665 ↗ |
| EDGAR ↗ | Jul 23, 2015 D File 021-244279 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 22, 2015 D File 021-232710 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 18, 2014 D/A File 021-200099 | $0 | $150,000 | $250,000 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 30, 2014 D/A File 021-204828 | $0 | $0 | $0 The Issuers are obligated to pay a management fee to the General Partner (or an affiliate thereof). | None listed on this filing |
| EDGAR ↗ | Mar 18, 2014 D File 021-213802 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 20, 2013 D/A File 021-186287 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 28, 2013 D File 021-190878 | $0 | $0 | $250,000 (est.) | None listed on this filing |
| EDGAR ↗ | Jan 25, 2013 D File 021-190823 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 17, 2012 D File 021-185678 | $0 | $0 | $250,000 (est.) | None listed on this filing |
| EDGAR ↗ | Oct 3, 2012 D File 021-184931 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 10, 2012 D File 021-182573 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 10, 2012 D File 021-182535 | $0 | $0 | $250,000 (est.) | None listed on this filing |
| EDGAR ↗ | May 14, 2012 D File 021-178148 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 13, 2012 D File 021-176710 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Mar 23, 2012 D File 021-175482 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 23, 2012 D File 021-175486 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 23, 2012 D File 021-175439 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 23, 2012 D File 021-175440 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 29, 2012 D File 021-174152 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Feb 29, 2012 D File 021-174156 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Feb 24, 2012 D File 021-173909 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 29, 2011 D File 021-163700 | $0 | $0 | $300,000 (est.) | None listed on this filing |
| EDGAR ↗ | Jul 29, 2011 D File 021-163704 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | May 20, 2011 D File 021-160157 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 13, 2011 D File 021-159829 | $0 | $0 | $250,000 (est.) | None listed on this filing |
| EDGAR ↗ | Feb 10, 2011 D File 021-155170 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 1, 2011 D File 021-154689 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 30, 2010 D File 021-152765 | $0 | $0 | $250,000 (est.) | None listed on this filing |
| EDGAR ↗ | Dec 30, 2010 D File 021-152783 | $0 | $0 | $250,000 (est.) | None listed on this filing |
| EDGAR ↗ | Sep 23, 2010 D File 021-148086 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 7, 2010 D File 021-147339 | $0 | $0 | $250,000 (est.) | None listed on this filing |
| EDGAR ↗ | Sep 2, 2010 D File 021-147266 | $0 | $0 | $50,000 (est.) | None listed on this filing |
| EDGAR ↗ | Jul 13, 2010 D/A File 021-66427 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 11, 2010 D File 021-143333 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 27, 2010 D File 021-141171 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 6, 2010 D File 021-140208 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 27, 2009 D File 021-117391 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 19, 2009 D File 021-54969 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | ViaLase, Inc. | Director | Sep 3, 2024 | D/A | $45,181,755 similar: $829,831–$9,999,998 | $45,181,755 | 15 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | ViaLase, Inc. | Director | Apr 5, 2024 | D | $41,031,754 similar: $829,831–$9,999,998 | $38,157,812 | 6 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | ViaLase, Inc. | Director | Mar 8, 2024 | D/A | $3,500,000 similar: $829,831–$9,999,998 | $3,500,000 | 3 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | ViaLase, Inc. | Director | Jan 18, 2024 | D | $2,300,000 similar: $829,831–$9,999,998 | $2,300,000 | 3 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | TearClear Corp. | Director | Jul 13, 2023 | D | $15,961,748 similar: $1,694,259–$16,000,000 | $11,764,262 | 70 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | LENSAR, Inc. | Director | May 26, 2023 | D | $20,000,000 similar: $829,831–$9,999,998 | $20,000,000 | 1 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Neurolens, Inc. | Director | Sep 13, 2022 | D | $67,642,795 similar: $2,000,000–$19,999,994 | $67,642,795 | 31 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | TearClear Corp. | Director | Aug 16, 2022 | D/A | $10,000,000 similar: $1,694,259–$16,000,000 | $5,900,000 | 43 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Neurolens, Inc. | Director | Jun 27, 2022 | D/A | $15,000,000 similar: $2,000,000–$19,999,994 | $14,700,000 | 27 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | TearClear Corp. | Director | Apr 27, 2022 | D | $10,000,000 similar: $1,694,259–$16,000,000 | $5,000,000 | 40 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | ViaLase, Inc. | Director | Nov 19, 2021 | D | $27,287,919 similar: $829,831–$9,999,998 | $27,287,919 | 25 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Neurolens, Inc. | Director | Nov 17, 2021 | D | $12,000,000 similar: $2,000,000–$19,999,994 | $12,000,000 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Allegro Ophthalmics, LLC | Director | Oct 13, 2021 | D/A | $6,746,652 similar: $1,694,259–$16,000,000 | $5,423,284 | 6 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Allegro Ophthalmics, LLC | Director | Sep 10, 2021 | D | $6,746,652 similar: $1,694,259–$16,000,000 | $4,599,990 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Allegro Ophthalmics, LLC | Director | Oct 1, 2020 | D | $8,324,042 similar: $1,694,259–$16,000,000 | $8,324,042 | 15 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | TearClear Corp. | Director | Aug 19, 2020 | D/A | $25,967,377 similar: $1,694,259–$16,000,000 | $22,346,503 | 51 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | TearClear Corp. | Director | Jul 23, 2020 | D/A | $25,967,377 similar: $1,694,259–$16,000,000 | $22,246,504 | 50 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | TearClear Corp. | Director | Apr 28, 2020 | D | $25,967,377 similar: $1,694,259–$16,000,000 | $15,779,678 | 39 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Neurolens, Inc. | Director | Mar 12, 2020 | D/A | $23,999,998 similar: $2,000,000–$19,999,994 | $23,819,972 | 24 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | TearClear Corp. | Director | Feb 14, 2020 | D | $3,000,000 similar: $1,694,259–$16,000,000 | $2,790,000 | 32 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Allegro Ophthalmics, LLC | Director | Jan 30, 2020 | D/A | $6,738,545 similar: $1,694,259–$16,000,000 | $5,335,973 | 11 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Allegro Ophthalmics, LLC | Director | Dec 18, 2019 | D | $6,738,545 similar: $1,694,259–$16,000,000 | $5,000,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Neurolens, Inc. | Director | Dec 16, 2019 | D/A | $23,999,998 similar: $2,000,000–$19,999,994 | $22,994,979 | 20 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Equinox Ophthalmic, Inc. | Director | Sep 6, 2019 | D/A | $21,999,998 similar: $1,100,015–$10,001,163 | $13,422,100 | 11 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Equinox Ophthalmic, Inc. | Director | Aug 14, 2019 | D | $21,999,998 similar: $1,100,015–$10,001,163 | $13,389,979 | 10 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Neurolens, Inc. | Director | Aug 7, 2019 | D | $23,999,998 similar: $2,000,000–$19,999,994 | $15,174,995 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ViaLase, Inc. | Director | Apr 2, 2019 | D | $8,139,570 similar: $829,831–$9,999,998 | $8,139,570 | 7 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Oyster Point Pharma, Inc. | Director | Feb 27, 2019 | D | $92,999,999 similar: $1,694,259–$16,000,000 | $84,999,985 | 7 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | TearClear Corp. | Director | Feb 14, 2019 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $4,999,999 | 22 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Allegro Ophthalmics, LLC | Director | Jan 16, 2019 | D/A | $13,477,089 similar: $1,694,259–$16,000,000 | $10,271,606 | 14 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Dec 21, 2018 | D | $2,999,991 similar: $2,000,000–$19,999,994 | $2,999,991 | 2 similar: 2–16 | $1,000,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Allegro Ophthalmics, LLC | Director | Dec 21, 2018 | D | $13,477,089 similar: $1,694,259–$16,000,000 | $10,000,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Oct 23, 2018 | D | $3,997,718 similar: $2,000,000–$19,999,994 | $3,997,718 | 2 similar: 2–16 | $1,000,000 similar: $10,000–$50,000 |
| EDGAR ↗ | AcuFocus, Inc. | Director | Aug 20, 2018 | D | $26,000,000 similar: $2,000,000–$19,999,994 | $23,974,000 | 15 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Aug 17, 2018 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $5,000,000 | 2 similar: 2–16 | $1,000,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Prelude Corp | Director | Jul 27, 2018 | D | $8,999,991 similar: $2,000,000–$19,999,994 | $8,999,991 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Edwards Lifesciences Corp | Director | Jun 1, 2018 | D | $34,869,330 similar: $2,000,000–$19,999,994 | $34,869,330 | 25 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CorneaGen Inc. | Director | May 15, 2018 | D | $2,000,000 similar: $829,831–$9,999,998 | $2,000,000 | 1 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | CorneaGen Inc. | Director | Apr 19, 2018 | D | $5,000,000 similar: $829,831–$9,999,998 | $5,000,000 | 1 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Neurolens, Inc. | Director | Dec 27, 2017 | D/A | $14,000,000 similar: $2,000,000–$19,999,994 | $13,121,905 | 35 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Oyster Point Pharma, Inc. | Director | Oct 25, 2017 | D | $43,125,784 similar: $1,694,259–$16,000,000 | $28,614,800 | 8 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Allegro Ophthalmics, LLC | Director | Jul 10, 2017 | D | $13,668,480 similar: $1,694,259–$16,000,000 | $10,721,508 | 17 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | TearClear Corp. | Director | May 31, 2017 | D/A | $4,631,151 similar: $2,000,000–$19,999,994 | $4,631,149 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | TearClear Corp. | Director | May 19, 2017 | D | $4,631,151 similar: $2,000,000–$19,999,994 | $2,386,149 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | RxSight, Inc. | Director | Apr 3, 2017 | D/A | $77,499,999 similar: $829,831–$9,999,998 | $49,975,202 | 62 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Prelude Corp | Director | Mar 15, 2017 | D | $5,499,998 similar: $2,000,000–$19,999,994 | $5,499,998 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | RxSight, Inc. | Director | Mar 8, 2017 | D | $77,499,999 similar: $829,831–$9,999,998 | $38,660,643 | 28 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Edwards Lifesciences Corp | Director | Feb 8, 2017 | D | $272,371,872 similar: $2,000,000–$19,999,994 | $272,371,872 | 25 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Versant Venture V AIV Feeder Holdings, L.P. group: Versant Venture | Director Manager of the General Partner of the Issuer | Nov 16, 2016 | D | $5,342,623 similar: $155,000–$5,250,000 | $5,342,623 | 7 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Versant Venture V AIV, L.P. group: Versant Venture | Director Manager of the General Partner of the Issuer | Nov 16, 2016 | D | $21,939,788 similar: $155,000–$5,250,000 | $21,939,788 | 32 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | CorneaGen Inc. | Director | Oct 18, 2016 | D | $10,000,000 similar: $829,831–$9,999,998 | $10,000,000 | 1 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | AcuFocus, Inc. | Director | Oct 5, 2016 | D | $74,924,639 similar: $2,000,000–$19,999,994 | $74,924,639 | 19 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AcuFocus, Inc. | Director | Aug 24, 2016 | D | $2,000,000 similar: $2,000,000–$19,999,994 | $2,000,000 | 15 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AEON Biopharma, Inc. | Executive Officer, Director Chairman of the Board | Aug 10, 2016 | D | $55,000,000 similar: $829,831–$9,999,998 | $5,500,000 | 5 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Prelude Corp | Director | Mar 15, 2016 | D | $3,000,000 similar: $2,000,000–$19,999,994 | $2,150,002 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AEON Biopharma, Inc. | Executive Officer, Director Chairman of the Board | Nov 20, 2015 | D | $150,000,000 similar: $829,831–$9,999,998 | $80,060,118 | 28 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | OneFocus Vision, Inc. | Director | Jul 23, 2015 | D | $2,201,285 similar: $829,831–$9,999,998 | $2,201,285 | 4 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | AEON Biopharma, Inc. | Executive Officer, Director Chairman of the Board | Jan 22, 2015 | D | $40,500,005 similar: $829,831–$9,999,998 | $27,000,015 | 5 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Jul 18, 2014 | D/A | $12,000,000 similar: $2,000,000–$19,999,994 | $11,000,000 | 5 similar: 2–16 | $1,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Versant Venture Capital V, L.P. group: Versant Venture | Director Managing Director of the General Partner of the Issuers | Jun 30, 2014 | D/A | $300,000,000 similar: $155,000–$5,250,000 | $295,515,306 | 86 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Jun 25, 2014 | D/A | $10,500,000 similar: $2,000,000–$19,999,994 | $6,000,000 | 0 similar: 2–16 | $1,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Oculeve, Inc. | Director | Mar 18, 2014 | D | $16,649,997 similar: $829,831–$9,999,998 | $16,649,997 | 8 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | Versant Venture Capital V, L.P. group: Versant Venture | Director Managing Director of the General Partner of the Issuers | Oct 18, 2013 | D | $250,000,000 similar: $500,000–$16,420,250 | $0 | 0 similar: 2–28 | No minimum reported similar: $5,000–$100,000 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Jul 23, 2013 | D | $10,500,000 similar: $2,000,000–$19,999,994 | $0 | 0 similar: 2–16 | $1,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Oculeve, Inc. | Director | Mar 20, 2013 | D/A | $7,592,976 similar: $829,831–$9,999,998 | $7,590,476 | 9 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Jan 28, 2013 | D | $25,000,000 similar: $2,000,000–$19,999,994 | $0 | 0 similar: 2–16 | $1,000 similar: $10,000–$50,000 |
| EDGAR ↗ | GLAUKOS Corp | Director | Jan 25, 2013 | D | $30,000,002 similar: $829,831–$9,999,998 | $30,000,002 | 20 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Oculeve, Inc. | Director | Oct 30, 2012 | D | $7,565,476 similar: $829,831–$9,999,998 | $7,565,476 | 8 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Oct 17, 2012 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $0 | 0 similar: 2–16 | $1,000 similar: $10,000–$50,000 |
| EDGAR ↗ | GLAUKOS Corp | Director | Oct 3, 2012 | D | $6,000,000 similar: $829,831–$9,999,998 | $6,000,000 | 11 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | GLAUKOS Corp | Director | Aug 10, 2012 | D | $4,500,000 similar: $829,831–$9,999,998 | $4,500,000 | 14 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Aug 10, 2012 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $0 | 0 similar: 2–16 | $1,000 similar: $10,000–$50,000 |
| EDGAR ↗ | NEOVISTA INC | Executive Officer, Director | May 14, 2012 | D | $6,273,000 similar: $829,831–$9,999,998 | $5,185,055 | 15 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Apr 13, 2012 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $0 | 0 similar: 2–16 | $2,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Versant Side Fund II, LP group: Versant Venture | Director Managing Director of the General Partner of the Issuer | Mar 23, 2012 | D | $3,575,000 similar: $155,000–$5,250,000 | $3,575,000 | 16 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | VERSANT AFFILIATES FUND I-A LP group: Versant Venture | Director Managing Director of the General Partner of the Issuer | Mar 23, 2012 | D | $5,175,000 similar: $155,000–$5,250,000 | $5,175,000 | 37 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | VERSANT SIDE FUND I LP group: Versant Venture | Director Managing Director of the General Partner of the Issuer | Mar 23, 2012 | D | $5,000,000 similar: $155,000–$5,250,000 | $5,000,000 | 18 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | VERSANT AFFILIATES FUND I-B LP group: Versant Venture | Director Managing Director of the General Partner of the Issuer | Mar 23, 2012 | D | $11,625,000 similar: $155,000–$5,250,000 | $11,625,000 | 72 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Feb 29, 2012 | D | $2,000,000 similar: $2,000,000–$19,999,994 | $2,000,000 | 0 similar: 2–16 | $2,000 similar: $10,000–$50,000 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Feb 29, 2012 | D | $2,000,000 similar: $2,000,000–$19,999,994 | $2,000,000 | 0 similar: 2–16 | $2,000 similar: $10,000–$50,000 |
| EDGAR ↗ | NEOVISTA INC | Director | Feb 24, 2012 | D | $1,001,000 similar: $829,831–$9,999,998 | $1,000,458 | 16 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Jul 29, 2011 | D | $16,150,000 similar: $2,000,000–$19,999,994 | $0 | 0 similar: 2–16 | $2,000 similar: $10,000–$50,000 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Jul 29, 2011 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $0 | 0 similar: 2–16 | $10,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Cameron Health, Inc. | Director | May 20, 2011 | D | $107,178,246 similar: $829,831–$9,999,998 | $82,670,840 | 62 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | May 13, 2011 | D | $6,300,000 similar: $2,000,000–$19,999,994 | $3,000,000 | 5 similar: 2–16 | $1,000 similar: $10,000–$50,000 |
| EDGAR ↗ | NEOVISTA INC | Director | Feb 10, 2011 | D | $37,879,999 similar: $829,831–$9,999,998 | $33,784,545 | 19 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | GLAUKOS Corp | Director | Feb 1, 2011 | D | $29,500,003 similar: $829,831–$9,999,998 | $29,500,003 | 18 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Dec 30, 2010 | D | $3,800,000 similar: $2,000,000–$19,999,994 | $1,900,000 | 10 similar: 2–16 | $1,000 similar: $10,000–$50,000 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Dec 30, 2010 | D | $3,500,000 similar: $2,000,000–$19,999,994 | $3,500,000 | 10 similar: 2–16 | $1,000 similar: $10,000–$50,000 |
| EDGAR ↗ | GLAUKOS Corp | Director | Sep 23, 2010 | D | $6,000,392 similar: $829,831–$9,999,998 | $6,000,392 | 11 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Sep 7, 2010 | D | $3,000,000 similar: $2,000,000–$19,999,994 | $1,500,000 | 10 similar: 2–16 | $1,000 similar: $10,000–$50,000 |
| EDGAR ↗ | SECOND SIGHT MEDICAL PRODUCTS INC | Director | Sep 2, 2010 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $5,000,000 | 19 similar: 2–16 | $1,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Inogen Inc | Director | Jul 13, 2010 | D/A | $10,000,000 similar: $829,831–$9,999,998 | $9,645,996 | 8 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | NEOVISTA INC | Director | Jun 11, 2010 | D | $12,012,000 similar: $500,000–$7,000,000 | $3,203,200 | 18 similar: 2–14 | $1 similar: $5,000–$50,000 |
| EDGAR ↗ | NEOVISTA INC | Director | Apr 27, 2010 | D | $3,003,000 similar: $500,000–$7,000,000 | $3,003,000 | 17 similar: 2–14 | $1 similar: $5,000–$50,000 |
| EDGAR ↗ | DOSE Medical Corp | Director | Apr 6, 2010 | D | $74,492 | $74,492 | 43 | No minimum reported |
| EDGAR ↗ | Inogen Inc | Director | Mar 2, 2010 | D | $10,000,000 similar: $829,831–$9,999,998 | $4,522,998 | 7 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | LENSX LASERS INC | Director | Mar 27, 2009 | D | $22,360,578 similar: $2,000,000–$19,999,994 | $22,360,578 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NEOVISTA INC | Director | Mar 19, 2009 | D | $18,000,000 similar: $500,000–$7,000,000 | $17,159,890 | 18 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (7 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Not linked to this profile — a second identifier (same issuer, same sponsor group) was not found. Could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as William Link. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when William Link appears on a new Form D, or when a court case or SEC action is matched to them. See plans →